CoVID-19 Molecular screening for Institutions and individuals
Check this page for information on NANO4 CoVID-19 molecular screening service
(service applies only to Portugal)
Nano4 Global is a young start-up launched in 2015 to market innovative nanotechnology based molecular diagnostics.
Nano4 is pioneering a new high-confidence proprietary nanotechnology platform relying on more than 12 years of research and development at Universidade NOVA de Lisboa - Science and Technology, Department of Life Sciences.
Our Values and Quality Policy
NANO4 is ISO 13485:2016 and ISO 9001:2015 Certified Company
NANO4 Global is ISO 13485:2016 and ISO 9001:2015 certified company, the higher level of ISO standards. These certifications are a requirement for regulatory purposes. ISO 13485:2016 is an international standard that outlines the requirements for a quality management system specific to the medical devices industry.
An extraordinary year for Nano4 Global - all objectives achieved and start of molecular diagnostics for CoVID-19.
Nano4 Global has a fully dedicated manufacturing lab. Located near Lisbon within a pharmaceutical campus hosting a Portuguese pharma company in Portugal. Nano4 Global manufacturing capability offer molecular diagnostic production and custom nanotechnology proficiency.
NANO4 Platform relies on a colorimetric molecular diagnostic method based on gold nanoparticles that provide fast and specific identification of a DNA or RNA biomarker.
NANO4 platform provides a colorimetric molecular diagnostic method based on gold nanoprobes that allow fast and specific identification of a DNA or RNA biomarker. The friendly use of Nano4 nanodiagnostics puts forward a fast, accurate, affordable technology - the next generation of molecular nanodiagnostics.
NANO4 is the next generation of molecular nanodiagnostics applied to life sciences that provides simple readout depending on the biomarker.
NANO4 is an award winning technology - Santander Totta/NOVAScientific Prize.
Gold nanoprobes provide a visual
colorimetric change to identify
the desired DNA/RNA sequence.
- fast colorimetric output
- affordable and user friendly
(no dedicated apparatus needed)
Due to the easy and simple operation, NANO4 will impact the way molecular diagnostics are performed and will lead the decentralization of molecular diagnostics - from genetics lab to point of need.
|BLANK||Gold nanoprobes provide a visual colorimetric change that identifies a DNA/RNA sequence.|
|POSITIVE||Target DNA/RNA prevents aggregation. Solution remains RED after revelator.|
|NEGATIVE||Gold nanoprobes aggregates in contact with a revelator. color changes RED to BLUE|
|Gold nanoprobes provide a visual colorimetric change that identifies a DNA/RNA sequence.|
|Target DNA/RNA prevents aggregation. Solution remains RED after revelator.|
|Gold nanoprobes aggregates in contact with a revelator. color changes RED to BLUE|
NANO4 platform is extremely flexible and easily adapted to a range of applications where specific DNA or RNA sequence is critical, such as detection of human pathogens (validation ongoing for M. tuberculosis, Zika), selected cancers and other genetic diseases.
Granted with SME phase 2 in 2018: 1,4 M€ grant
Granted with SME phase 1 in 2017
Granted with P2020 non-dilutive fund in 2018
Appointed as one of the 30 most innovative companies in Portugal at NOS Awards 2017
One of the 66 companies selected to the programme Road to Websummit 2016
Gold Nanoparticles Platform was recognized in 2012 with Santander Totta / Universidade Nova Lisboa awarded of technology